SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

CSPC reports anbenitamab reduced death risk in advanced stomach cancer Phase III trial

Valid market news retained in the public archive without immediate LiveCast distribution.

CSPC

Related stories